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Background: Intrinsically fluorescent glucose derived carbon nanospheres (CSP) efficiently enter mammalian cells
and also cross the blood brain barrier (BBB). However, the mechanistic details of CSP entry inside mammalian cells
and its specificity are not known.
Results: In this report, the biochemical and cellular mechanism of CSP entry into the living cell have been
investigated. By employing confocal imaging we show that CSP entry into the mammalian cells is an ATP-
dependent clathrin mediated endocytosis process. Zeta potential studies suggest that it has a strong preference for
cells which possess high levels of glucose transporters such as the glial cells, thereby enabling it to target individual
organs/tissues such as the brain with increased specificity.
Conclusion: The endocytosis of Glucose derived CSP into mammalian cells is an ATP dependent process mediated
by clathrin coated pits. CSPs utilize the surface functional groups to target cells containing glucose transporters on
its membrane thereby implicating a potential application for specific targeting of the brain or cancer cells.Background
Nanomaterials are being currently explored for various
biomedical applications. In particular, carbon based
nanomaterials such as single walled and multi-walled
carbon nanotubes are increasingly being used as drug
delivery vehicles. For imaging and efficient drug delivery,
these nanomaterials are often tagged with some fluores-
cent agents and antibodies [1-3]. We had earlier
reported amorphous carbon nanospheres [4] derived
from glucose which are intrinsically fluorescent, non-
toxic and have the ability to deliver the drug molecules
inside the nucleus. Detailed in vivo studies showed that
they were effectively removed from the animal system
within a month and hence could be considered as poten-
tial carrier vehicle for therapeutic applications. However,
to exploit the complete therapeutic potential of any car-
rier, the mechanism of its entry, preference of cell types
and retention in the system needs to be thoroughly
investigated.* Correspondence: tapas@jncasr.ac.in
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reproduction in any medium, provided the orIn this study, we report the mechanism behind the cel-
lular entry of CSPs and therefore it’s utility as a cell type
specific targeting delivery agent. We have elucidated that
CSP entry is predominantly a clathrin mediated and
ATP dependent endocytic process. The rich functional
surface groups and the charge on CSP gives them a
unique ability to preferentially target cells with more
glucose transporters such as the glial cells thus strength-
ening the possibility of CSP to be used as a potential
drug delivery system targeted to the brain.Results and discussions
Carbon nanospheres ranging from 100–500 nm in size
were synthesized [4] and tested for their ability to
traverse the mammalian cell membrane. The CSP exhi-
bits a time dependent entry with respect to different cel-
lular regions. Within 3 hrs of incubation at 37°C, CSP
could enter mammalian cells [4]. The large size and
charged surface of CSP rules out the probability of entry
into mammalian cells through diffusion. The most com-
mon method of particle uptake by cells is either a pas-
sive diffusion mechanism or an active process involving
the energy obtained after hydrolysis of ATP. Since, the
passive diffusion allows only liquids, gases or very smalld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sible. This led us to speculate that the uptake of CSP
into cells is through endocytosis which is an active
process. This was investigated by using the human cer-
vical cancer cell line, HeLa. To determine, whether the
CSP uptake is by receptor mediated endocytosis process,
CSPs were incubated with the cells at different tem-
peratures [5,6] : 4°C, 25°C and 37°C for 12 hours. The
quantification of CSP present in the cells reveals that
at 4°C (upon 12 hrs incubation) only 8-9% is localized
inside the cell, whereas upon increasing temperature of
incubation, the percentage entry increased substan-
tially. At 37°C, it was found to be around 35-40% con-
sidering total number of cells to be 100% (Figure 1A
and B). As low temperature blocks receptor mediated
endocytosis [6], efficient CSP internalization observed at
higher temperature could be predominantly mediated by
endocytosis. As it is known that in mammalian cells the
ATP synthesis and utilization is maximum near 37°C [7]
the uptake of CSP by the HeLa cells could be ATP hy-
drolysis derived energy dependent. The requirement of
ATP for the uptake of CSP was investigated by using a
medium containing sodium azide or 2-deoxy-D-glucose
(2DDG) which leads to depletion of the intracellular pool
of ATP [8-11]. The depletion of ATP level was confirmed
by quantifying the total intracellular ATP pool using a
luciferase based assay system kit (Figure 1E) [12,13]. Pre-
treatment with sodium azide or 2DDG blocked the entry
of CSP into the cells (Figure 1C and D) suggesting the in-
volvement of ATP in the uptake of CSP. Since the low
temperature inhibits formation of the active form of cla-
thrin pits [14]; the clathrin mediated endocytosis could
be operative for CSP uptake.
Endocytosis is the phenomenon by which cells
internalize membrane proteins, lipids, extracellular
ligands and soluble molecules. One of the earliest stud-
ied endocytotic pathways is the clathrin mediated
process [15]. In addition, a variety of other clathrin-
independent pathways have also been characterized in-
cluding phagocytosis, macropinocytosis, caveolae- and
raft-mediated uptake [16] and a poorly characterized
form of constitutive clathrin-independent endocytosis.
We performed a simple receptor blocking experiment by
treating the cells with sucrose that created a hypertonic
environment in the medium which prevents the forma-
tion of clathrin coated pits and thus further blocks re-
ceptor mediated endocytosis [17-19]. In agreement with
the temperature dependent entry of the CSP into the
cells, it was observed that hypertonic media [19] almost
completely excluded the entry of CSP into mammalian
cells incubated at 37°C (Figure 2 A and B). Clathrin
mediated endocytosis pathways require dynamin which
is required for the formation of coated vesicles [20] . To
establish further the involvement of clathrin in theendocytosis of CSP, we treated the cells with a dynamin
inhibitor, dynasore [21]. Pretreatment of dynasore for
30mins prevented CSP internalization into the HeLa
cells (Figure 2 C and D). Furthermore, the colocaliza-
tion of CSP and clathrin was also performed by fluor-
escence microscopy using anti-clathrin antibody to
visualize the clathrin mediated endocytosis of CSP.
Predominant localization of clathrin was observed in the
regions enriched with CSP near the plasma membrane
(Figure 2E). Collectively these results, suggests that CSP
uptake by mammalian cells is an ATP dependent
process that is primarily through clathrin mediated
endocytic pathway.
We have previously observed that the CSPs by virtue
of their surface functional groups [4] are capable of
crossing the blood brain barrier (BBB), to elucidate the
mechanistic details that facilitate the CSP entry across
the BBB; we decided to test the CSP uptake on cell types
present in the BBB as well as other tissue origins. For
this purpose, we selected a mouse embryonic fibroblast
NIH3T3 cell line, and cancerous cell lines of different
tissue origins such as adenocarcinoma cell line of the
neuronal origin SHSY-5Y, glioblastoma cell line
U373MG and human cervical HeLa.
As depicted in the figure, SHSY-5Y cells showed CSP
uptake of 23%, NIH3T3 and HeLa cells showed CSP up-
take ability of 32% and 39% respectively whereas
U373MG cells showed 52% CSP uptake after 12 hrs
time-point (Figure 3A). Even though there was no dras-
tic difference in the cellular uptake of CSP between the
two time points (12 and 24 h), uptake by U373 cell line
was higher in comparison with NIH3T3 and SHSY-5Y
cells, whereas uptake by HeLa cells was moderate
(Figure 3B). There are several aspects that could con-
tribute to these differences in the cell type specific up-
take of CSP a possible reason could be density of
glucose transporters on the cell surface. Immunoblot-
ting analysis on U373 cells revealed that these cells ex-
press very high levels of glucose transporters GLUT1
and GLUT4 (Figure 3C). HeLa cells which also exhibit
a moderate uptake of CSPs also expressed GLUT4
apart from GLUT1 which is present in all the tested
cell types. GLUT1 is one of the most abundant glu-
cose transporters present in the blood brain barrier
and glial cells which facilitates transport of glucose
molecules across the cell membrane [22]. The hydroxyl
group of glucose molecule possesses high affinity to-
wards GLUT1. Glucose molecules are involved in
hydrogen bonding with the transmembrane alpha heli-
ces of GLUT1 [23]. As CSP contains free hydroxyl
groups on its surface, it might interact with glucose
transporters and facilitates the uptake of CSP.
In order to support these observations we further car-
ried out the cell surface charge measurements, which
Figure 1 The CSP uptake is an energy dependent process. A. CSPs were incubated with HeLa cells at different temperatures (4°C, 25°C, 37°C)
for 12 hours and were then fixed with 4% paraformaldehyde. The cells were then stained with Hoechst and were imaged using confocal
microscope. B. Quantification for percentage of CSP uptake. C. ATP dependence of CSP entry was monitored by incubating CSP with HeLa cells
pretreated with 2-deoxy-D-glucose and sodium azide. The panels are representative images of the cells in the presence or absence of ATP. D.
Quantification for percentage of CSP uptake. E. Quantification of the total pool of intracellular ATP by using an ATP quantification kit (Invitrogen).
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The cellular uptake of nanoparticles generally involves
the binding of nanoparticles on the cell surface followed
by internalization using a specific endocytosis pathway
[24-26]. During this process, the cell zeta potential (a
measure of its surface charge) would be changed. Cell
membrane, in general, imparts a negative charge to the
cell surface giving rise to a negative zeta potential for
the cell. Binding of nanoparticles on the cell surface willchange the zeta potential of the cell by, a) influencing
the adsorption characteristics of the ions present around
its surface and b) shifting the surface of hydrodynamic
shear. When attached to the cell surface, negatively
charged nanoparticles will make the cell zeta potential
more negative, while positively charged nanoparticles
will make the cell zeta potential less negative or positive.
The internalization of nanoparticles by endocytosis leads
to the cell zeta potential less negative. In order to study
Figure 2 The CSP uptake is mediated by clathrin dependent endocytosis. A. HeLa cells were incubated with CSP in a hypertonic medium
containing 0.45 M sucrose for 12 hrs and were then fixed with 4% paraformaldehyde. The cells were then stained with Hoechst and were imaged
using confocal microscope. B. Quantification for percentage of CSP uptake. C. HeLa cells pretreated with or without 100 μM dynasore (an
inhibitor of dynamin) for 30 mins and were then incubated with CSP for 12 hrs. D. Quantification for percentage of CSP uptake with or without
dynasore treatment. E. Co localization of CSP with clathrin in HeLa cells, Panel I is the enlarged image of E, panel II-IV are independent replicates of E.
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carried out zeta potential measurements of the cell sur-
face, after incubating them for different durations with
CSPs. The zeta potential of CSPs in HEPES buffer (pH
7.4) is −8.0 ± 0.6 mV (Figure 4), which is less negativecompared to the value obtained in pure water
(−24 mV). The zeta potential value for U373 glial cells
in HEPES buffer was found to be −11.1 ± 0.4 mV. Upon
incubation of these cells with CSP for 30 minutes, the
zeta potential became more negative, -23.1 ± 0.7 mV
Figure 3 CSP uptake across different cell types. A. SHSY-5Y (adenocarcinoma cell line of the neuronal origin), U373 (glioblastoma cell line),
NIH3T3 (mouse embryonic fibroblast) and HeLa (human cervical cancer) cells were incubated with 10 μg/ml of CSP. After either 12 hrs or 24 hrs,
cells were washed with PBS and were fixed with 4% paraformaldehyde and were stained with Hoechst and were imaged using confocal
microscope. CSP was visualized by exciting at 514 nm. Scale bar represents 10 μm. B. Quantification for percentage of CSP uptake by different cell
lines at two different time points. C. Western blots for presence of GLUT1 and GLUT4 in different cell lines. Tubulin was used as a loading control.
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are attached to the cell surface. Allowing the incubation
time to 2 h, significantly brings the zeta potential of the
cells close to their original value (−11.0 ± 1.0 mV), indi-
cating the internalization of the CSPs. No notable vari-
ation in the zeta potential of these cells could be
observed by increasing the incubation time from 2 hr to
12 hr (Figure 4, red bars). Thus the internalization
process (of CSP) in U373cells completes within 2 hr of
incubation. In contrast to the U373 cells which contains
higher amounts of glucose receptor, a different trend
was observed for NIH3T3 and HeLa cells (zeta potential
in HEPES buffer), which contains lesser amounts of glu-
cose receptors in comparison to U373 cells. Even
though both the cell lines, HeLa and NIH3T3 took12 hrs to completely internalize CSP, almost 50%
internalization was observed in the 2 hrs timepoint for
HeLa cells (Figure 4, blue bars) whereas CSP uptake was
much lesser in NIH3T3 cells at 2 hrs timepoint (Fig-
ure 4, cyan bars). This difference in the changes of the
cell zeta potential of different cell types for different
duration of incubation could be explained by presence
of the receptors on their cell membrane. Glial U373
cells are highly enriched with the glucose transporters
GLUT1 on their surface while HeLa has moderate and
NIH3T3 has the least levels. So, the affinity of CSP,
which could mimic the glucose functionality on its sur-
face, towards U373 cells will be very high as compared
to the other cell lines. The zeta potential of U373 cells
becomes highly negative by 30 minutes of incubation
Figure 4 Zeta potential of different cell type after treatment with CSP. Zeta potential of different cell types viz. U373 cells, HeLa and NIH3T3
cells were measured in 40 mM HEPES buffer (pH 7.4) upon 30 minutes, 2 hours, and 12 hours of incubation with 10 μg/ml of CSP.
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sorption, which results in preferred uptake of CSP by
this cell line.
Previously, it was reported that CSP could cross the
blood brain barrier and enter the mice brain [4]. It was
also observed in the liver and spleen, however, brain tis-
sue showed maximum localization of CSP [4]. Since the
mammalian brain is highly enriched with glia [27], and
various glucose transporter proteins are also known to
be localized on the brain capillary endothelial cell mem-
branes that forms the BBB [28,29], the present observa-
tions of CSP preference to the glial cells and its
preference towards glial cells also supports the previous
report of increased brain localization, to be primarily
mediated through the surface functionality of CSP. To
further verify this preferential cellular targeting on spe-
cific brain cell types, the availability of CSP in different
regions of the brain was investigated. CSP injected mice
were sacrificed after 3 days and their brain was isolated,
fixed with paraformaldehyde, sectioned and processed
for confocal imaging analysis. Confocal microscopy of
different brain parts (cerebral cortex and cerebellum)
were performed for the presence of CSP by excitation at
514 nm. CSPs were predominantly localized in the cere-
bral cortex region with very minimal presence in cere-
bellum (Figure 5). We have observed an increased
preference of CSP towards glial cells which could be
correlated with higher population of glial cell lineages in
the cerebral cortex of the brain than in the cerebellum
[27,30,31].These observations suggest that the glucose derived
CSP by virtue of their surface charge possess unique abil-
ity to not just traverse the cell membrane but also exhibit
a preference towards the cells with more number of glu-
cose transporters on its surface. By virtue of its interaction
with glucose transporters, it crosses the blood brain bar-
rier and reaches the brain cells through the involvement
of ATP dependent clathrin mediated endocytosis. ATP
dependent clathrin mediated endocytosis plays fundamen-
tal role in neurotransmission and signal transduction [32].
Presence of higher levels of clathrin in brain in compari-
son to other tissue also partly answers the more specificity
of CSP towards the brain [32,33]. Clathrin vesicles are also
one of the major components of vesicle mediated endo-
cytosis pathway in the synapses of various regions of brain
involved in different phenomena [34-36]. Furthermore,
predominant distribution of GLUT1 on the BBB that trans-
fer glucose across the barrier is exploited by various neu-
roactive drugs to cross the BBB [37]. Thus GLUT1 in
association with other glucose transporters might be related
to the mechanism of CSP to cross the BBB. After reaching
the brain through the glial cells, CSP may get transferred
to other brain cells like neurons through association with
other glucose transporters (presumably GLUT3).
Conclusion
We elucidated the mechanism of CSP uptake by mam-
malian cells and found that it is predominantly clathrin
dependent ATP driven process. CSP prefers cells expres-
sing more number of glucose transporters thus providing
Figure 5 Predominant localization of CSP in the cerebral cortex region of the brain. A. CSP (10 mg per kg of body weight) was
intraperitoneally injected in mice and after 3 days, they were sacrificed and their brains were isolated and immediately fixed in 4%
paraformaldehyde. Sections of different brain regions were obtained and were processed for histochemical analysis. Hoechst was used to stain
the nucleus and the cells were imaged using a confocal microscope. CSP was visualized by exciting at 514 nm.
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specificity towards glial cells for crossing the BBB, as glial
cells containing GLUT1 are major components of the
endothelial cells of the BBB. Once it reaches the brain it
gets carried to various cell types including the neurons.
Presently, when nanomaterials are being tested for their
ability to deliver important drug molecules across different
cells, tissues, a nanomaterial such as CSP which can pre-
ferentially target the brain cells, implies an important spe-
cific targeting mechanism which can be extensively
exploited against several brain associated disease condi-
tions such as the neurodegenerative states. Furthermore,
the preference of CSP towards cell types with increased
glucose transporters implicates its utility for targeting dis-
ease states wherein these levels are perturbed.
Methods
Cell lines
HeLa, SHSY-5Y, NIH3T3 and U373MG cells were grown
in Dulbecco’s modified eagle’s medium with 10% FBS
and antibiotics at 37°C in presence of 5% CO2 in a hu-
midified chamber.
Fluorescence studies
Cells were grown on poly L-lysine coated coverslips and
were treated with 10 μg/ml of CSP. After 12 or 24 hrs of
treatment, cells were washed in PBS and were fixed
with 4% paraformaldehyde. Hoechst (Sigma) was used
to stain the nucleus and the fluorescence was visua-
lized using Carl Zeiss LSM 510 META laser scanning
confocal microscope. CSP fluorescence was visualized
at 560 nm by excitation at 514 nm.
ATP depletion
HeLa cells were pretreated with 10 mM sodium azide
and 30 mM 2-deoxy-D-glucose for two hours and were
then incubated with CSP for 12 hrs. Followingincubation cells were fixed with 4% paraformaldehyde.
Hoechst (Sigma) was used to stain the nucleus and the
fluorescence was visualized using Carl Zeiss LSM 510
META laser scanning confocal microscope.
Determination of intracellular ATP levels
Intracellular levels of ATP in HeLa cells after treat-
ments with 2DDG (Calbiochem) or sodium azide was
determined by using an ATP determination kit from
Molecular Probes, Invitrogen [12,13]. Briefly, cells were
boiled in TE for 5mins before analysis and Lumines-
cence was measured using Wallac 1409 Liquid scintilla-
tion counter.
Clathrin blockage
HeLa cells were pretreated with media containing
0.45 M sucrose or 100 μM dynasore for 30mins and
were then incubated with CSP for 12 hrs. Cells were
then fixed and processed for confocal imaging.
Mice brain immunofluorescence
BALB/c mice were injected intra-peritoneally with
10 mg per kg of body weight of CSP, 3 days post in-
jection, they were sacrificed and their brains were im-
mediately fixed in 4% paraformaldehyde. The brain
tissues were dehydrated, paraffin embedded, and sec-
tioned into 4 micron thick sections using a microtome
(Leica). The tissue sections were stained with Hoechst
and were visualized using Carl Zeiss LSM 510 META
laser scanning confocal microscope. CSP fluorescence
was visualized at 560 nm by excitation at 514 nm.
Zeta potential measurements
The mammalian cells were incubated in the presence of
CSP for different time points and were harvested by
trypsinization. The cell pellets were resuspended in
700 μl of 40 mM HEPES buffer (pH 7.4). The zeta
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for different time duration viz. 30 minutes, 2 hours, and
12 hours, were measured using Zetasizer Nano ZS (Mal-
vern Instruments). All the measurements were carried
out at 25°C using phase analysis light scattering mode.
The Zeta (ξ) potential was calculated from the electro-
phoretic mobility based on the Smoluchowski equation,
u = Eξ/η, where u is the measured electrophoretic mobil-
ity, ξ is zeta potential value; E is the dielectric constant η
is the viscosity of the electrolytic solution.
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